On September 8, Luoxin Pharmaceuticals Group Stock Co.,Ltd. (002793) announced that Chen Xian has resigned from her position as Chief Financial Officer due to work reassignment, with the resignation taking effect from September 5, 2025. Following her departure from the CFO role, Chen will assume the position of Deputy Director of the company's Innovation Operations Management Office. As of the announcement date, Chen does not hold any shares in the company.

The company held a board meeting on September 8, 2025, and appointed Wu Yongsheng as the new Chief Financial Officer. His term will commence from the date of board approval and continue until the expiration of the fifth board of directors' tenure.

Wu Yongsheng holds a master's degree and possesses qualifications as an intermediate accountant and certified public accountant. He has previously served in financial management positions at multiple companies. As of the announcement date, Wu does not directly hold company shares but indirectly owns 400,000 shares through participation in the company's 2024 employee stock ownership plan. He has no affiliated relationships with shareholders holding more than 5% of the company's shares or other senior management personnel.

For the first half of 2025, Luoxin Pharmaceuticals reported revenue of 1.077 billion yuan and net profit attributable to shareholders of 17.7 million yuan.